Adaptive Phage Therapeutics, Inc. (APT) a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, announced the opening of their state-of-the-art BSL2 labs and phage manufacturing facilities designed to FDA GMP ICH Q7A and ISO Class 5 standards. The 7,200-square foot facility is strategically located in Gaithersburg, Maryland – within 25 miles of FDA, BDRD, NMRC, Walter Reed Military Hospital, Johns Hopkins, and NIH. APT’s facilities are unique as they were designed from the ground up specifically for manufacturing patient specific therapeutic phage products. In 2016, APT entered into a collaborative research and development agreement (CRADA) with the Naval Medical Research Center (NMRC) and has negotiated worldwide exclusive rights to NMRC’s innovative system for phage/pathogen rapid matching (patents pending), as well as proprietary datasets, and PhageBank®.
In what has become an annual tradition, MedImmune and BioHealth Innovation Inc., have brought the BioHeath Capital Region together for the 4th Annual BioBowl at Bowlmore Rockville. Over 40 companies were invited to compete against each other for the BioBowl Trophy for the top team, and to avoid “winning” the infamous Rubber Chicken Trophy for the most “challenged” performance. The team from Qiagen collectively scored higher than all others and had their name added to the BioBowl Trophy for 2017.
The event is split in half with attendees playing with their company teams for the 1st hour, and then being mixed-up into random teams to create a fun networking opportunity. BioBowl was born out of an early CEO dinner for the BioHealth Capital Region with the goal of bringing together the community for a fun event that also helps companies build relationships with each other.
Caption: Jarrod Borkat of MedImmune and Rich Bendis of BHI presenting the Champions Trophy to Qiagen
American Gene Technologies (AGT), a private Maryland biotechnology company developing cures and treatments for Infectious diseases, cancers and monogenic disorders hosted a ribbon cutting October 23, 2017 celebrating the grand opening of its new 24,000 sq. ft. laboratory and offices. From its new location, AGT will begin clinical trials for its HIV Functional Cure therapeutic in the next six months.
A plan to build 12M SF of mixed-use development on a 300-acre site near the Food and Drug Administration’s HQ in Montgomery County has been in the works for nearly a decade, and the developer feels confident it can break ground in a matter of months.
United Therapeutics Corp (NASDAQ: UTHR), which has an office in the Research Triangle, has received approval of a new inhalation device from the U.S. Food and Drug Administration (FDA) for use with its drug Tyvaso. Tyvaso, has been the focal point of a number of patent disputes. A treatment for pulmonary hypertension (PAH), the drug generates significant sales for the company.
Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies have entered into an exclusive global collaboration and license agreement for MacroGenics’ MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.
After seeing the strength of the six finalist projects and evaluating each of the teams’ proposals, TEDCO board members decided to up their $300,000 offer, and fund every one of them.
Imagine walking into your doctor appointment and not only receiving a thoroughly researched diagnosis, but a menu of treatment options that match your condition, lifestyle and health goals.
1ST Biotherapeutics, Inc. (1ST Bio), a private Korean biotech company, and Neuraly Inc., a startup from Johns Hopkins School of Medicine, today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson’s disease. Recent research has shown that inhibitors to c-Abl could slow the progression of Parkinson’s disease. Parkinson’s disease, a chronic and progressive movement disorder, is the second most common neurodegenerative disease, affecting nearly one million people in the United States.
The University System of Maryland (USM) institutions have released a “Statement Supporting Open Access Dissemination of Scholarship,” a joint statement created by the university libraries of all 12 USM campuses. Councils representing the faculty, students, and the presidents of USM’s universities have collectively endorsed the statement. The statement explains the potential benefits to researchers who choose to make their works “freely available online either immediately upon completion, or within specified limited periods.”
OpGen, Inc. (NASDAQ:OPGN) today announced that it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) to develop smartphone-based clinical decision support solutions for antimicrobial stewardship (AMS) and infection control in low- and middle-income countries. The one-year $860,000 award began September 30, 2017 and funds development and evaluation of cloud-based mobile software. OpGen will work with partners Teqqa, LLC and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc.
Mayo Clinic and United Therapeutics Corp. can start construction on the foundation for their proposed lung-restoration center at Mayo’s Southside campus.
Imagine that Baltimore’s street lights automatically came on when they sensed someone was near, collected data about air quality and even alerted police at the sound of a gunshot.
How can Johnson & Johnson Innovation (JJI) help you reach your goals? We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a diverse team of science and transaction experts whose goal is to find high potential early-stage innovation and, if on strategy and a fit for Johnson & Johnson, create customized deal structures to help accelerate the science to the patient.
Six companies presenting innovative medical device solutions that address significant unmet needs in pediatric health were awarded a total of US$250,000 in grant money in San Jose, Calif. at the Fifth Annual Pediatric Device Innovation Symposium, organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.
Thursday, November 30, 2017 from 6:15 p.m. to 8:30 p.m. at Inova Center for Personalized Health 3225 Gallows Road, Fairfax VA
The Inova Personalized Health Accelerator has made it our mission to increase the speed at which innovation enters the health system.
To celebrate this new venture we’re kicking off with a launch event to inspire, align, and connect our talented professionals, dedicated investor base and up-and-coming innovative startups in the area.
A vision on healthcare and medicine in 2025; customer & patient experiences will change dramatically due to AI, IoT, Cloud driven disruption:
It’s time for your annual checkup! A phlebotomist will conveniently visit you at home in the early morning and take your blood (while you are lying relaxed, since it makes a difference to your metabolome if you are lying or sitting), possibly also collecting samples of saliva as well as urine and stool samples your intelligent toilet was sampling and preserving for later microbiome, metabolome, proteome analytics . The service for onsite blood sampling and the technology is there; see IggBo video.
Diabetes has long been one of the most expensive medical conditions. In 2013 spending on care for people with the disease in the United States topped $100 billion. But it is also one of the most amenable to simple, low-cost behavioral interventions. At Geisinger, we set out to improve the health of diabetic adults by providing them with free, nutritious food and a comprehensive suite of medical, dietetic, social, and environmental services.
LOCATION: Institute for Bioscience and Biotechnology Research (IBBR), 9600 Gudelsky Dr., Rockville, MD 20850
TIME: Thursday, November 30, 2017 – 3:00pm to 5:00pm
NIIMBL was formed to leverage a $70 million cost-shared agreement sponsored by the National Institute of Standards and Technology (NIST) into a $270 million public-private partnership to promote innovative technologies in bio-manufacturing in America. This information session will provide an overview of NIIMBL and explain how your organization can get involved!
The JLABS: 5 Years of Innovation report quantifies the impact that JLABS and its companies have had on the innovation ecosystem during the past five-years, including investments raised, jobs created and diversity of leadership.
Want to boost your brain power? Researchers at Johns Hopkins think they have a solution.
There are countless programs out there claiming to help improve your brain function. To date, none of them have been proven to be effective. But researchers at Johns Hopkins recently compared two exercises thought to improve brain power, specifically your working memory (not your IQ), which can help you handle a number of work and school-related tasks easier.
Until recently, serial entrepreneur Naveen Jain’s most ambitious project was Moon Express, a literal moonshot that aims to land a rocket on our cratered neighbor and use its resources to make other planets livable for humans. His newest mission feels just as profound: create a world without chronic disease.
Every marketer wants the perfect story to tell. But if you’re in medicine, you don’t want it to be about yourself.
Earlier this year, vascular surgeon John Martin was testing a pocket-sized ultrasound device developed by Butterfly Network, a startup based in Guilford, Connecticut, that he’d just joined as chief medical officer.
The best Data Scientists see in a slew of data what matters, communicate why it matters, and instruct others about how strategy and operations must change to address what matters.
Expert advisory firm Newport Board Group, LLC continues to expand locally, announcing today the admission of Martin Rosendale, a life sciences entrepreneur and executive as a member of the LLC and Partner in its Mid-Atlantic practice.
